Top 50 Life Science Startup Investors in China (October 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
Prox Ventures
VC Fund
|
8 | China, United States, United Kingdom | Seed, Series A | Medical, Biotechnology, Health Care | $2.5M–$30M |
|
Qiming Venture Partners
VC Fund
|
7 | China, United States, Hong Kong | Series B, Series A, Series C | Health Care, Biotechnology, Medical | $4.3M–$120M |
|
Linear Capital
VC Fund
|
6 | China, Singapore, United States | Seed, Angel, Series A | Artificial Intelligence, Software, Manufacturing | $1.4M–$122M |
|
HSG
VC Fund
|
6 | China, United States, Singapore | Series A, Series B, Seed | Artificial Intelligence, Software, Health Care | $2M–$200M |
|
Lenovo Capital and Incubator Group (LCIG)
VC Fund
|
5 | China, Hong Kong, United States | Series A, Seed, Series B | Manufacturing, Artificial Intelligence, Software | $1.4M–$150M |
|
Hillhouse Investment
VC Fund
|
5 | China, United States, Singapore | Series B, Series A, Series C | Biotechnology, Health Care, Software | $2.9M–$230M |
|
Baidu Ventures
VC Fund
|
4 | China, United States, Singapore | Series A, Seed, Series B | Artificial Intelligence, Health Care, Robotics | $1.5M–$123M |
|
Vinno Capital
VC Fund
|
4 | China, United States | Series A, Seed, Series B | Manufacturing, Semiconductor, Medical | $1.4M–$139M |
|
Dalton Venture
VC Fund
|
4 | China, India, Canada | Seed, Series A, Series B | Health Care, Medical, Biotechnology | $512k–$50M |
|
Matrix Partners China
VC Fund
|
4 | China, United States, Singapore | Series A, Series B, Seed | Health Care, Software, Biotechnology | $1.2M–$137M |
|
EFung Capital
VC Fund
|
4 | China, United States, India | Series A, Series B, Series C | Health Care, Biotechnology, Medical | $1.4M–$100M |
|
Hillhouse Ventures
VC Fund
|
4 | China, Singapore, Norway | Series A, Series B, Seed | Manufacturing, Biotechnology, Health Care | $10M–$120M |
|
Huagai Capital
VC Fund
|
4 | China, United States, Hong Kong | Series A, Series B, Angel | Health Care, Medical, Biotechnology | $425k–$90M |
|
CD Capital
VC Fund
|
3 | China, United States | Series A, Series B, Seed | Health Care, Biotechnology, Medical Device | $1.4M–$34M |
|
Jiadao Capital
VC Fund
|
3 | China | Seed, Angel, Series A | Biotechnology, Manufacturing, Medical | $1.4M–$49M |
|
Cenova
VC Fund
|
3 | China, United States, Hong Kong | Series B, Series A, Series C | Medical, Health Care, Biotechnology | $2.9M–$100M |
|
Haitang Fund
VC Fund
|
3 | China | Seed, Series A, Venture - Series Unknown | Manufacturing, Biotechnology, Medical | $1.5M–$103M |
|
Shenzhen Capital Group
VC Fund
|
3 | China, United States, Japan | Series A, Series B, Seed | Manufacturing, Health Care, Software | $1.4M–$141M |
|
Xinghua Dingli
VC Fund
|
3 | China | Seed, Series A, Series B | Biotechnology, Medical, Biopharma | $1.4M–$14M |
|
MiraclePlus
VC Fund
|
3 | China, United States, Singapore | Seed, Angel, Pre-Seed | Artificial Intelligence, Software, Information Technology | |
|
ULTIMA
VC Fund
|
3 | China | Angel, Series A, Series B | Health Care, Biotechnology, Fitness | $462k–$15M |
|
Northern Light Venture Capital
VC Fund
|
3 | China, United States, South Korea | Series A, Series B, Venture - Series Unknown | Health Care, Medical, Biotechnology | $1.5M–$60M |
|
ZSVC
VC Fund
|
3 | China, United States, India | Series A, Seed, Series B | Manufacturing, Medical, Health Care | $1.4M–$84M |
|
BioVenture
VC Fund
|
3 | China, United States, Hong Kong | Series A, Series B, Seed | Health Care, Biotechnology, Medical | $4.4M–$85M |
|
Shunxi Fund
VC Fund
|
3 | China | Series A, Seed, Series B | Biotechnology, Manufacturing, Artificial Intelligence | $2.4M–$90M |
|
Oriental Fortune Capital
VC Fund
|
3 | China, United States, Hong Kong | Series A, Series B, Seed | Manufacturing, Software, Artificial Intelligence | $1.5M–$100M |
|
WuXi AppTec
VC Fund
|
3 | United States, China, Israel | Series A, Series B, Series C | Biotechnology, Health Care, Pharmaceutical | $6M–$187M |
|
Entrepreneurship Relay Group
VC Fund
|
3 | China | Series A, Angel, Venture - Series Unknown | Manufacturing, Software, Enterprise | $1.5M–$30M |
|
Tianjin Venture Capital
VC Fund
|
3 | China, United States | Venture - Series Unknown, Seed | Manufacturing, Information Technology, Biotechnology | $462k–$41M |
|
Legend Capital
VC Fund
|
3 | China, United States, South Korea | Series B, Series A, Series C | Health Care, Medical, Biotechnology | $2.9M–$200M |
|
Inspiration Capital
VC Fund
|
3 | China | Seed, Series A, Angel | Manufacturing, Artificial Intelligence, Semiconductor | $1.5M–$16M |
|
Longpan Investment
VC Fund
|
3 | China, United States, Cayman Islands | Series A, Seed, Series B | Health Care, Medical, Biotechnology | $14M–$60M |
|
CITIC Capital Holdings
VC Fund
|
3 | China, United States, Japan | Series A, Series B, Series C | Manufacturing, Health Care, Biotechnology | $3.2M–$230M |
|
Jinqiu Fund
VC Fund
|
2 | China, United States, Hong Kong | Seed, Series A, Angel | Artificial Intelligence, Robotics, Manufacturing | |
|
Tsinghua Capital
VC Fund
|
2 | China, Australia | Seed, Angel, Series A | Manufacturing, Artificial Intelligence, Biotechnology | $425k–$73M |
|
Lucion
VC Fund
|
2 | China | Series A, Series B | Biotechnology, Manufacturing, Medical | $1.4M–$539M |
|
Innoangel Fund
VC Fund
|
2 | China, Canada, Hong Kong | Angel, Seed, Series A | Artificial Intelligence, Robotics, Manufacturing | $425k–$27M |
|
Shangshi Fund
VC Fund
|
2 | China | Series A, Angel, Seed | Information Technology, Manufacturing, Artificial Intelligence | $283k–$73M |
|
Gaw Capital Partners
VC Fund
|
2 | China, Singapore, United States | Series A, Seed, Series C | Real Estate, Hotel, Internet | $3M–$250M |
|
Frees Fund
VC Fund
|
2 | China, United States, Singapore | Series A, Seed, Angel | Artificial Intelligence, Health Care, Biotechnology | $425k–$35M |
|
Ascendis Pharma
VC Fund
|
2 | China | Series A, Series B | Life Science, Biotechnology, Pharmaceutical | $40M–$40M |
|
Med-Fine Capital
VC Fund
|
2 | China, Hong Kong, United States | Series A, Seed, Series B | Medical, Health Care, Biotechnology | $3M–$60M |
|
Huimei Capital
VC Fund
|
2 | China, United States, Japan | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $10M–$251M |
|
BMC
VC Fund
|
2 | China | Seed, Series B | Biotechnology, Medical, Product Research | $1.4M–$14M |
|
Orient Securities Capital Investment
VC Fund
|
2 | China, Canada | Series A, Series B, Venture - Series Unknown | Manufacturing, Health Care, Software | $1.5M–$684M |
|
Vivo Capital
VC Fund
|
2 | United States, China, United Kingdom | Post-IPO Equity, Series B, Series C | Biotechnology, Health Care, Pharmaceutical | $28M–$180M |
|
ASBV
VC Fund
|
2 | China, Australia, Hong Kong | Seed, Series A, Angel | Health Care, Medical, Biotechnology | $471k–$34M |
|
Green Pine Capital Partners
VC Fund
|
2 | China, United States, Canada | Series A, Angel, Series B | Artificial Intelligence, Biotechnology, Manufacturing | $425k–$150M |
|
BOHE Angel Fund
VC Fund
|
2 | China | Angel, Seed, Series A | Health Care, Medical, Biotechnology | $1.4M–$100M |
|
Highlight Capital
VC Fund
|
2 | China, United States, South Korea | Series A, Series B, Seed | Health Care, Medical, Biotechnology | $3.1M–$84M |
| Access all 691 investors in China Life Science startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
Proxima Ventures focuses in the healthcare industry, supporting outstanding enterprises with innovative technologies or service models that have tremendous potential.They manage multiple funds in RMB and US dollar, covering from seed to growth stages. Their team members with multidisciplinary backgrounds and resourceful networks, have many yearsof remarkable venture capital experience and achievements. They believe that active and effective collaboration with entrepreneurs will make substantial economic returns while bring meaningful improvements in public health.
Show more...Investment focus
- Industry: Medical, Biotechnology, Health Care
- Stage:Seed, Series A
- Geography: China, United States, United Kingdom
Investor stats
- Total investments: 83
- Round size: Seed $2.5M–$30M; Series A $3M–$28M
- Lead/follow: 18% lead, 82% follow
Portfolio highlights
- BCI-Sonics — BCI-Sonics is an innovative medtech company developing non-invasive brain-computer interface solutions using advanced transcranial focused ultrasound (tFUS) technology. The company builds a next-generation therapeutic platform enabling precise neuromodulation to treat central nervous system disorders. BCI-Sonics develops low-intensity focusedultrasound technology that non-invasively stimulates deep brain regions with high precision. They combine ultrasound engineering and neuroscience to interface safely and effectively with the human brain without surgery. The company is creating an AI ultrasound brain-computer interface platform for therapeutic neuromodulation applications.
- Bluesail Surgical — Bluesail Surgical is a surgical device company that specializes in the development of innovative surgical instruments for cardiovascular and cerebrovascular treatments.
- Kingsung Medical Group — Kingsung Medical Group operates under the Mission “Simplify Surgery, Beautiful Life,” with its innovation centered on four core technology platforms at its Tianjin base: Mechanical Design, Polymer Materials, Biodegradable Magnesium Alloys, and Collagen Biomaterials. These platforms have enabled the development of pioneering medical devices,including microvascular anastomosis devices and neural tube. In particular, the Group’s biodegradable magnesium alloy technology is spearheading the advancement of next-generation orthopedic implants. Kingsung’s technological capabilities are evidenced by a portfolio of over 190 patents and its recognition as a National Key Enterprise. The Group also actively contributes to the industry as a standing council member of the Microsurgery Branch of the China Association of Medical Devices Industry and a member of the Chinese Society for Biomaterials.
Founded in 2006, Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Hong Kong in China, and Singapore.Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companiesin the Technology and Consumer (T&C) and Healthcare industries at the early and growth stages.Since our debut, we have backed over 530 fast-growing and innovative companies. Over 200 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or other means. There are also over 70 portfolio companies that have achieved unicorn or super unicorn status.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series B, Series A, Series C
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 1195
- Round size: Series A $4.3M–$48M; Series B $7.9M–$90M; Series C $12M–$120M
- Lead/follow: 51% lead, 49% follow
- Last fund: Likely actively investing — fresh fund, raised $8M in 2026
Portfolio highlights
- LP Amina — LP Amina focuses on products that improve coal-fired power plant's emissions and efficiency. Leveraging 50 unique patented products to improve the firing system of a coal-fired boiler, including Rotating Vane Wheels, High Performance Classifiers, Coal Pipe Balancing Technologies, and Burner Enhancements, the Company provides products andsolutions that will meet or exceed the expectations of their customers. Furthermore, LP Amina's corporate culture is one of a relentless pursuit of continuous improvement. Utilizing the latest technology and traditional know-how from the World's two largest users of Coal for power generation, the Company is well positioned to develop new products and solutions to meet the ever changing needs of Power Industry.LP Amina's staff has over 20 years of experience in the design, fabrication, installation and commissioning of coal-fired power plants. During this time, the team has gained a wide range of experience from the evolution of the US Power Market. Increases in environmental regulations and free market driven energy prices have forced plant operators to reduce emissions and improve reliability while lowering operational cost. LP Amina's engineering and design team will leverage this experience gained from the US and Europe to address the emergence of similar issues in China.
- Nice Tuan — Nice Tuan is an e-commerce platform that provides daily groceries and miscellaneous products.
- Shennapsi Artificial Intelligence Technology — Synapsor is a medical-grade wearable device research and development company, oriented to the AI+ medical and health field, and is committed to the development and manufacturing of AI-powered medical-grade smart wearable devices, including AI-ECG artificial intelligence. Diagnostic analysis system, CUMS uric acid blood glucose and cholesterolmonitoring system, etc. The company has recently received tens of millions of yuan in Series B investment, and the investor is Xiaomi Technology.
Linear Capital is a Frontier Tech Fund founded in 2014 by Harry Wang, Facebook's first Chinese R&D manager. We currently manage 10 funds with AUM of more than $2 billion.
Show more...Investment focus
- Industry: Artificial Intelligence, Software, Manufacturing
- Stage:Seed, Angel, Series A
- Geography: China, Singapore, United States
Investor stats
- Total investments: 96
- Round size: Seed $1.4M–$122M; Angel $1.4M–$122M; Series A $5.7M–$29M
- Lead/follow: 30% lead, 70% follow
- Last fund: Likely still investing — raised $300M in 2022
Portfolio highlights
- D-Robotics — D-Robotics is a leading provider of robotic computing solutions.
- Xieyue Intelligent — Xieyue Intelligent focuses on the research and development of embodied intelligence technology.
- DeepPu Intelligence — DeepPu Intelligence is a high-tech enterprise specializing in the research, development, and innovation of intelligent robotic technologies. The company focuses on creating advanced robotic systems that integrate artificial intelligence, machine vision, and automation to serve a wide range of industries, including manufacturing, logistics,healthcare, and service sectors.
HSG is a leading venture capital and private equity firm investing globally in the technology, healthcare, and consumer sectors.
Show more...Investment focus
- Industry: Artificial Intelligence, Software, Health Care
- Stage:Series A, Series B, Seed
- Geography: China, United States, Singapore
Investor stats
- Total investments: 1085
- Round size: Seed $2M–$50M; Series A $4M–$100M; Series B $11M–$200M
- Lead/follow: 45% lead, 55% follow
- Last fund: Likely still investing — raised $2.5B in 2024
Portfolio highlights
- Z.ai — The AI Lab behind GLM models, dedicated to inspiring the development of AGI to benefit humanity. https://t.co/gOw7WpwkJt https://t.co/ot9sGVXU8x
- BCI-Sonics — BCI-Sonics is an innovative medtech company developing non-invasive brain-computer interface solutions using advanced transcranial focused ultrasound (tFUS) technology. The company builds a next-generation therapeutic platform enabling precise neuromodulation to treat central nervous system disorders. BCI-Sonics develops low-intensity focusedultrasound technology that non-invasively stimulates deep brain regions with high precision. They combine ultrasound engineering and neuroscience to interface safely and effectively with the human brain without surgery. The company is creating an AI ultrasound brain-computer interface platform for therapeutic neuromodulation applications.
- Suisheng Technology — Suisheng Technology is an innovative company specializing in AI-driven memory services, dedicated to developing intelligent solutions that help individuals and businesses capture, organize, and retrieve important information with greater efficiency and precision.
Lenovo Capital and Incubator Group is an accelerator and venture capital firm.
Show more...Investment focus
- Industry: Manufacturing, Artificial Intelligence, Software
- Stage:Series A, Seed, Series B
- Geography: China, Hong Kong, United States
Investor stats
- Total investments: 346
- Round size: Seed $1.4M–$65M; Series A $1.5M–$74M; Series B $8M–$150M
- Lead/follow: 26% lead, 74% follow
- Last fund: May invest from a new fund soon — raised $500M in 2016
Portfolio highlights
- Deepin Technology — Deepin Technology is a company that utilizes artificial intelligence, quantum chemistry, and high-throughput experiment technologies to enhance the efficiency and workflow of chemical material innovation. it offers efficient R&D solutions for chemical materials, aiming to solve lab bottlenecks, promote innovative research, and enhance customervalue.
- SenseTime Medical — SenseTime Medical promotes the development and implementation of its medical big model and provides smart health solutions.
- Jiuwanli Future Technology — Jiuwanli Future Technology is an Integrated circuit design service provider.
Founded in 2005, Hillhouse is a leading global investment management firm, active across public equity, private equity, real estate and private credit. The firm invests over a long-term horizon and partners with exceptional entrepreneurs to deliver sustainable value creation for quality companies.Hillhouse is a full life-cycle private equityfirm, investing for the long term across opportunities in the healthcare, business services, consumer, and industrials sectors. The firm manages capital on behalf of global institutions such as non-profit foundations, endowments, and pensions.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Series B, Series A, Series C
- Geography: China, United States, Singapore
Investor stats
- Total investments: 331
- Round size: Series A $2.9M–$165M; Series B $15M–$230M; Series C $15M–$220M
- Lead/follow: 38% lead, 62% follow
- Last fund: May invest from a new fund soon — raised $11B in 2018
Portfolio highlights
- Sainte — Sainte is a company which provides professional nutritional solutions for babies with different nutritional needs
- Vita Dynamics — Vita Dynamics involves learning through real-world interactions by developing robots that can physically engage with their environment, they can adapt more naturally and efficiently.
- NeueHCT — Horizon Continental Technology is a joint venture between Continental Group and Horizon Robotics
Doma Protocol is a purpose-built blockchain to modernize and unlock the liquidity of over 362M existing and future domains
Show more...Investment focus
- Industry: Artificial Intelligence, Health Care, Robotics
- Stage:Series A, Seed, Series B
- Geography: China, United States, Singapore
Investor stats
- Total investments: 243
- Round size: Seed $1.9M–$28M; Series A $1.5M–$43M; Series B $8M–$123M
- Lead/follow: 22% lead, 78% follow
- Last fund: Likely still investing — raised $141M in 2023
Portfolio highlights
- Sondit — Sondit specializes in R&D and manufacturing of civilian radar systems. It includes intelligent transportation, intelligent security, vehicle-road coordination, and other fields. It engaged in traffic information monitoring and urban traffic management in the field of the intelligent transportation industry.
- Deepin Technology — Deepin Technology is a company that utilizes artificial intelligence, quantum chemistry, and high-throughput experiment technologies to enhance the efficiency and workflow of chemical material innovation. it offers efficient R&D solutions for chemical materials, aiming to solve lab bottlenecks, promote innovative research, and enhance customervalue.
- Differential Robotics — Differential Robotics is a robotics company providing research, design, and development of aerial robots and intelligent autonomous drones.
Vinno Capital focuses on early-stage venture investments in ICT and healthcare-related fields.
Show more...Investment focus
- Industry: Manufacturing, Semiconductor, Medical
- Stage:Series A, Seed, Series B
- Geography: China, United States
Investor stats
- Total investments: 41
- Round size: Series A $1.4M–$70M; Series B $11M–$139M
- Lead/follow: 49% lead, 51% follow
Portfolio highlights
- TianShu Yaoguang — Tianshu Yaoguang creates artificial intelligence systems for geometric design and optimization in advanced manufacturing.
- Ruimeng Semiconductor — Ruimeng Semiconductor is a provider of intelligent human-machine interface processor chips and solutions.
- Baisheng Smart Computing — Baisheng Smart Computing specializes in the field of information technology application innovation, operations, and maintenance.
Dalton Venture is a fund management company that specializes in early stage investment and industrial mergers and acquisitions in the field of big health.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Seed, Series A, Series B
- Geography: China, India, Canada
Investor stats
- Total investments: 143
- Round size: Seed $512k–$5M; Series A $3M–$17M; Series B $3.2M–$50M
- Lead/follow: 38% lead, 62% follow
Portfolio highlights
- Vibronix — Vibronix innovates for Precision Healthcare with spectroscopic imaging, optical & acoustic sensing, and machine learning.
- PowerMicro — PowerMicro focuses on the cutting-edge interdisciplinary field of “stem cells + engineered scaffolds,” specializing in the application of iPSC technology to advance regenerative medicine, tissue engineering, and innovative therapeutic solutions.
- NewPro — NewPro is in the process of increasing production and establishing regulations for lactoferrin raw materials, with the goal of bringing the product to market as quickly as feasible.
Matrix Partners China builds long-term relationships with entrepreneurs and helps them build significant, industry-leading companies.Since its inception in 1977, Matrix Partners China has made hundreds of investments and played an active role in the development of many successful businesses, 50 of which went on to IPO, and 75 of which have goneon to profitable M&A events. The firm consistently ranks in the top venture firms in terms of returns to its investors.Matrix Partners China combines local knowledge with global experience and vision. Its team consists of both former entrepreneurs and experienced investors. Its past successes include Focus Media, Eachnet, and Baidu, among others. The company invests across multiple sectors and stages.
Show more...Investment focus
- Industry: Health Care, Software, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: China, United States, Singapore
Investor stats
- Total investments: 706
- Round size: Seed $1.2M–$74M; Series A $2.9M–$52M; Series B $10M–$137M
- Lead/follow: 37% lead, 63% follow
- Last fund: Likely still investing — raised $92M in 2023
Portfolio highlights
- Camera360 — Camera360 is a professional but easy-to use App for photo editing and selfie retouching. Tag #camera360
- BCI-Sonics — BCI-Sonics is an innovative medtech company developing non-invasive brain-computer interface solutions using advanced transcranial focused ultrasound (tFUS) technology. The company builds a next-generation therapeutic platform enabling precise neuromodulation to treat central nervous system disorders. BCI-Sonics develops low-intensity focusedultrasound technology that non-invasively stimulates deep brain regions with high precision. They combine ultrasound engineering and neuroscience to interface safely and effectively with the human brain without surgery. The company is creating an AI ultrasound brain-computer interface platform for therapeutic neuromodulation applications.
- Liepin — Liepin is the largest and most professional high-end talent community-based recruitment site, with its innovative products and unique service model model for create an interactive high-end talent recruitment platform between business, headhunting and workplace. Tens of thousands of professional executive search consultant for businesses and jobseekers set up communication between the bridge and accelerate corporate recruitment process, recommended paying jobs in the workplace, career development planning. 16 job seekers to avoid the risk of privacy protection, millions of high-end elite member libraries, help enterprises development needs.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Shenzhen EFUNG Investment Management Enterprise L. P. is one of China's earliest institutions investing in professional biomedical industries. Their strong research team and great investment returns made us won 'The Most Pioneering VC Institution” 'The Most Dynamic Pharmaceutical VC Institution in China' and 'The Top Ten VCInstitutions in Shenzhen'. With this influence, EFUNG has drawn a lot of attention from the medical and life science industry. And it is interviewed by Nature, which is the most authoritative science magazine in the world. Over a decade of years, they have been focusing on the medical and health industry, especially the VC and PE investment business of novel drugs and high-end medical devices. The mission of EFUNG is to drive the industrialization of medical researches by capital and to gain rich returns to investors. EFUNG has deeply screened and invested in more than 20 domestic and international premium enterprises, such as Chipscreen Biosciences, Frontier Biotechnologies, Ascentage Pharma, Lifotronic, Aridis Pharmaceuticals, and Centrexion.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Series B, Series C
- Geography: China, United States, India
Investor stats
- Total investments: 85
- Round size: Series A $1.4M–$36M; Series B $14M–$100M; Series C $14M–$74M
- Lead/follow: 35% lead, 65% follow
Portfolio highlights
- Xinyun Life — Xinyun Life Sciences is a high tech medical enterprise focusing on the R&D and industrialization of artificial intelligence vascular intervention devices. The company integrates AI deeply into its hardware development using a unique dual closed- oop system.
- Glimmer Gene — Glimmer Gene develops a comprehensive gene editing and epigenetic toolkit with independent intellectual property rights.
- Yuewei Medical — Yuewei Medical is a developer of cardiac surgery interventional medical devices.
Hillhouse Venture Capital is an investment institution established by Hillhouse Capital that focuses on investing in early-stage startups.
Show more...Investment focus
- Industry: Manufacturing, Biotechnology, Health Care
- Stage:Series A, Series B, Seed
- Geography: China, Singapore, Norway
Investor stats
- Total investments: 77
- Round size: Seed $10M–$120M; Series A $10M–$85M; Series B $14M–$99M
- Lead/follow: 44% lead, 56% follow
Portfolio highlights
- Yatsen Holding — Yasten provides high-quality fashion makeup products.
- kaye technology — Kaye Technology is a company that provides automation upgrade solutions for beverage equipment.
- Deepin Technology — Deepin Technology is a company that utilizes artificial intelligence, quantum chemistry, and high-throughput experiment technologies to enhance the efficiency and workflow of chemical material innovation. it offers efficient R&D solutions for chemical materials, aiming to solve lab bottlenecks, promote innovative research, and enhance customervalue.
Huagai Capital is a private equity investment firm that invests in start-up or growth companies in the areas of healthcare, TMT, and culture.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Series B, Angel
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 153
- Round size: Angel $425k–$15M; Series A $1.5M–$73M; Series B $8.5M–$90M
- Lead/follow: 41% lead, 59% follow
- Last fund: May invest from a new fund soon — raised $430M in 2018
Portfolio highlights
- SeaArt — SeaArt AI is an all-in-one AI creativity community for art, videos, audio, and AI chats, where creators collaborate, spark inspiration, and grow together.
- Zhiran Medical — Zhiran Medical is a medical technology company specializing in the precise detection and treatment of neurological disorders using high-throughput, flexible brain-computer interface technology.
- GigaAI — Excellent Vision is a spatial intelligence company focused to transforming video creation into a 4D world model, enabling AI big models to grasp, generate, and reason about 4D space.
CD Capital is a venture capital firm specialized in life sciences and medical technology. They are currently managing both RMB and USD funds with total size of $600M. CD Capital is operated by a professional team with diversified and profound industry backgrounds. They have made over 40 investments with high growth potential and earned a reputationas a premier venture capital firm with main focus on China healthcare industry. With broad network around China and the world, they have been able to seize the global trend, capture investment opportunities as well as help to define the future for China healthcare industry. Ultimately, they strive to grow best-in-class companies and deliver solid financial return to their investors.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical Device
- Stage:Series A, Series B, Seed
- Geography: China, United States
Investor stats
- Total investments: 73
- Round size: Seed $1.4M–$15M; Series A $1.5M–$32M; Series B $7.6M–$34M
- Lead/follow: 37% lead, 63% follow
Portfolio highlights
- Genlight — Genlight develops innovative treatment solutions for epilepsy and other neurological diseases. Genlight is headquartered in Hangzhou, China.
- Pipi Bear — Pipi Bear is a creator of living robots and health goods, with a focus on those that improve the lives of the elderly.
- CORE Biomedicine — CORE Biomedicine is a private, preclinical-stage biotechnology company that specializes in drug discovery and development for oncology.
Jiadao Capital is an investment Firm.
Show more...Investment focus
- Industry: Biotechnology, Manufacturing, Medical
- Stage:Seed, Angel, Series A
- Geography: China
Investor stats
- Total investments: 24
- Round size: Seed $2.2M–$15M; Angel $1.4M–$49M; Series A $15M–$15M
- Lead/follow: 33% lead, 67% follow
Portfolio highlights
- Garen Semiconductor — Garen Semiconductor focuses on the R&D, production and sales of semiconductor materials (such as gallium oxide).
- Yongquan Innovation — Yongquan Innovation is a technological firm that specializes in sophisticated desktop CNC machinery.
- Active Technology — Active Technology is a pioneering deep tech startup specialized in developing invasive brain computer interface (BCI) technology. The company integrates flexible electrodes, dedicated chips, and advanced decoding algorithms to target motor, visual, and emotional neural pathways.
Cenova Capital is one of the earliest healthcare dedicated funds in China founded in 2010 by Dr Jun WU and is one of the earliest investors in private healthcare services and digital health, with helps to facilitate the transformation of healthcare in China from an exclusively state-owned system to a more efficient, market-oriented system. CenovaCapital is healthcare funds dedicated to early and growth-stage investments in the life sciences and healthcare sector in China. Since inception in 2010, Cenova now has five funds under management with investments in over 50 companies in healthcare services, pharmaceuticals, medical devices and digital heath. Cenova's investors are mainly large domestic and international institutional investors including Asian sovereign wealth funds, government institutions, insurance and financial institutions and multinational companies.
Show more...Investment focus
- Industry: Medical, Health Care, Biotechnology
- Stage:Series B, Series A, Series C
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 60
- Round size: Series A $2.9M–$45M; Series B $13M–$61M; Series C $15M–$100M
- Lead/follow: 50% lead, 50% follow
Portfolio highlights
- Simnova — Simnova Biotherapeutics is a biopharmaceutical company that focuses on the research and development of cell therapies for cancer treatment. The company's primary therapeutic focus is CAR-based cell therapy for patients with either hematologic malignancies or solid tumors. Simnova Biotherapeutics is known for its innovative approach todeveloping patient-centered therapeutics using current science and technology. The company's lead product is SNC102, a cell therapy product that has been approved for clinical trials. Simnova Biotherapeutics is committed to creating a healthy, inclusive, and harmonious working environment.
- Deep Cell — Deep Cell is a Chinese AI driven drug discovery and virtual cell modeling startup. The company integrates artificial intelligence with multi scale molecular physics to construct explainable virtual cell world models, aiming to revolutionize paradigm shifting drug designs and simulate cellular responses to complex diseases.
- Accro Bioscience — Accro Bioscience research centers on the molecular mechanism of regulated cell death such as necroptosis, pyroptosis, and ferroptosis.
Haitang Fund is a venture capital fund jointly established by Tianjin University alumni entrepreneurs and other alumni and entrepreneurs.
Show more...Investment focus
- Industry: Manufacturing, Biotechnology, Medical
- Stage:Seed, Series A, Venture - Series Unknown
- Geography: China
Investor stats
- Total investments: 51
- Round size: Seed $7.9M–$15M; Series A $1.5M–$103M; Venture - Series Unknown $14M–$44M
- Lead/follow: 29% lead, 71% follow
Portfolio highlights
- MemoraX AI — MemoraX AI is an innovator in the field of tailored memory for huge models.
- Yuantian Bio — Yuantian Bio is a biotechnology company specializing in enzymatic regeneration and commercial plastic PET applications. They have achieved low-cost fermentation preparation of over 10 enzyme preparations and large-scale biochemical product preparation.
- Xingkan Jiuzhou — Xingkan Jiuzhou is a technology-based enterprise specializing in radio signal reception, demodulation, analysis, and transmitter location.
Shenzhen Capital Group Co., Ltd (“SCGC”) is a limited venture capital company established by the Shenzhen Government in 1999. Since its establishment, SCGC has focused on cultivating national industries, shaping national brands, promoting economic transformation, and emerging industries developing. SCGC has registered capital of 5.42 billion RMB,and a total AUM of 338.99 billion RMB. SCGC primarily invests in SMEs, innovative high-tech enterprises, enterprises in emerging industries, and enterprises in start-up period, growth period and in transformation, covering industries supported by national policies, including IT, internet, new media, biopharma, new energy, environmental protection, chemical engineering, new material, high-end equipment manufacturing, consumption goods, modern service, etc. By the end of April 2019, SCGC ranked the first based on the number of portfolio companies and the number of listed portfolio companies: 994 portfolio companies, investments totaling 43.9 billion RMB, 145 of which have been listed in 16 capital markets worldwide.
Show more...Investment focus
- Industry: Manufacturing, Health Care, Software
- Stage:Series A, Series B, Seed
- Geography: China, United States, Japan
Investor stats
- Total investments: 645
- Round size: Seed $1.4M–$29M; Series A $1.6M–$122M; Series B $4.9M–$141M
- Lead/follow: 42% lead, 58% follow
- Last fund: Likely actively investing — fund raised in 2025
Portfolio highlights
- Prosemi — Pusenmei is a precision micro-resistance current sensor developer company committed to delivering professional and diverse precision micro-resistance current detecting resistors and circuit protection solutions.
- Enrikenuo — Enrikenuo is a biotechnology company that focuses on the research and development of new generation CAR-NK technology based cell drugs.
- Waker Biology — Weike Bio is a gene therapy drug development company.
Xinghua Dingli is an investment company.
Show more...Investment focus
- Industry: Biotechnology, Medical, Biopharma
- Stage:Seed, Series A, Series B
- Geography: China
Investor stats
- Total investments: 13
- Round size: Seed $1.4M–$14M
- Lead/follow: 46% lead, 54% follow
Portfolio highlights
- Puyuan Bio — Puyuan Bio engages in the clinical quantitative detection of tumor-specific mRNA in human peripheral blood. Its technology can provide an important clinical diagnosis basis for the presence of hematogenous spread of tumor cells and dynamic monitoring of the disease.The company has a talented team with doctoral tutors, doctors, and masters as themain body, and has 9 national invention patents in related fields. The company was approved by the Ministry of Science and Technology of Science and Technology Small and Medium Enterprises Technology Innovation Fund and passed the acceptance inspection. It is an enterprise settled in the technology transfer plan of Anhui Province and has been included in the Hefei Shuangqian Project. It was supported by the Development and Reform Commission in 2018.The registration application materials of the cytokeratin 19 (CK19) mRNA nucleic acid detection kit (PCR-fluorescent probe method) have been accepted by the State Food and Drug Administration, the on-site inspection of the medical device production quality management standard has been passed, and the approval number will be obtained soon. When it is put into production, it will contribute to public health.
- Kaiwang Data — Kaiwang Data is a one-stop shop for data solutions. It focuses on offering complete data labeling solutions for automakers and businesses involved in autonomous driving.
- Gaowei Medicine — Gaowei Medicine is a drug discovery platform for developing new drugs for key intractable diseases such as cancer and neurological diseases.
MiraclePlus invests in and accelerates early-stage startups. MiraclePlus assists startups in developing products that are good enough to succeed in the market. MiraclePlus' acceleration program works with the founders to get each team in top shape so that they can present to thousands of investors on Demo Day.
Show more...Investment focus
- Industry: Artificial Intelligence, Software, Information Technology
- Stage:Seed, Angel, Pre-Seed
- Geography: China, United States, Singapore
Investor stats
- Total investments: 76
- Lead/follow: no public data
Portfolio highlights
- TestSprite — AI powered fully automated end-to-end testing solutions to help enterprises launch their products faster.
- Excellent Vision — Excellent Vision is a spatial intelligence company focused to transforming video creation into a 4D world model, enabling AI big models to grasp, generate, and reason about 4D space.
- Gongji Technology — Gongji Technology is an idle computing power sharing platform that combines distributed computing power with leading scheduling techniques to address elastic computing power requirements.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!ULTIMA is an investment management firm.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Fitness
- Stage:Angel, Series A, Series B
- Geography: China
Investor stats
- Total investments: 7
- Round size: Angel $462k–$1.6M; Series A $1.5M–$15M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Maimai — Maimai provides software and hardware smart care solutions for middle-to-high-end institutions, senior citizens, communities and home care.
- Mol Breeding — Mol Breeding is a biotech firm that focuses on animal and plants molecular breeding technology R&D and services.
- HC Scientific — HC Scientific is a high-tech enterprise integrating research, development, production and sales of a new biomedical system
Supporting the next generation of entpreneurs in enterprise, healthcare, and consumer with disruptive potential.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Series B, Venture - Series Unknown
- Geography: China, United States, South Korea
Investor stats
- Total investments: 397
- Round size: Series A $2.9M–$40M; Series B $8.8M–$56M; Venture - Series Unknown $1.5M–$60M
- Lead/follow: 27% lead, 73% follow
- Last fund: Likely still investing — raised $375M in 2021
Portfolio highlights
- Flytech — Flytech specializes in crystal materials and related components for magneto-optical-electrical integrated signal processing.
- Moge Microflow — Moge Microflow is a manufacturer of equipment for microreactors. It provides continuous flow production technologies and equipment for nanomaterials, pharmaceutical intermediates, and fine chemicals, as well as standardized high-end microreactor equipment.
- Bianzhong New Materials — Bianzhong New Materials is a high-tech company that specializes in the research and development of equipment for weaving and shaping three-dimensional preforms of high-strength fiber composite materials.
ZSVC is a Chinese venture capital firm specialized in seed and early stage investments.
Show more...Investment focus
- Industry: Manufacturing, Medical, Health Care
- Stage:Series A, Seed, Series B
- Geography: China, United States, India
Investor stats
- Total investments: 147
- Round size: Seed $1.4M–$4M; Series A $1.5M–$21M; Series B $3.1M–$84M
- Lead/follow: 29% lead, 71% follow
Portfolio highlights
- Tpson — Tpson is a Smart Hardware company.
- Ounuo Semiconductor — Ounuo Semiconductor is a manufacturing company that provides research and development of semiconductor equipment.
- HUAXI Technology — HUAXI Technology is a global leader specializing in the development and delivery of comprehensive, high-end smart elderly care solutions. By integrating advanced technologies such as the Internet of Things (IoT), artificial intelligence (AI), and big data analytics, the company is dedicated to enhancing the quality of life for seniors worldwide.
Suzhou Industrial Park Bioventure Investment Management Limited (Bioventure) was established in September 2013. Bioventure its first element of the new bio-industry funds 540 million yuan fund size. Bioventure specialize in the field of life sciences in the early stages of the venture capital investments as having high strength and growth, greaterdevelopment space, excellent management team, biotechnology, drug discovery, medical devices and healthcare services companies, and provide capital, management , operation and other aspects of post-investment support and services.Bioventure brought together senior investment professionals team with bio-pharmaceutical industry investment experience, strong fund management, entrepreneurship and venture capital and operating experience in business, have a deep understanding of the domestic and foreign markets, capable of its forward-looking international perspective and extensive The industry has the potential resources to help innovative companies grow rapidly and gain greater success, while giving fund investors bring considerable returns.Suzhou Industrial Park, the core investor BioBay has the country's best medical and pharmaceutical incubator function, use the platform, the project team has great resources and industrial service advantages, Yuan-sheng venture has successfully invested in 20 projects have been cast projects in their own development and follow-up financing, has made outstanding achievements in the industry for all to see, and won the Venture's trust and praise.By focusing and extensive industry resources, Bioventure determined to become one of China's most successful medical and pharmaceutical venture fund. Bioventure expectations and in the medical and pharmaceutical industry where there joint venture development cooperation.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Series B, Seed
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 192
- Round size: Seed $7.9M–$41M; Series A $4.4M–$47M; Series B $7.1M–$85M
- Lead/follow: 33% lead, 67% follow
- Last fund: May invest from a new fund soon — raised $204M in 2016
Portfolio highlights
- Inno Medicine — Inno Pharmaceutical Technology specializes in research on the pathogenesis of atherosclerosis. The company focuses on the development of targeted nanoliposomes, targeting molecules with independent intellectual property rights, and currently focuses on the plaque reversal treatment of atherosclerosis.
- Zhiran Medical — Zhiran Medical is a medical technology company specializing in the precise detection and treatment of neurological disorders using high-throughput, flexible brain-computer interface technology.
- MyoGene Life Sciences — MyoGene Life Sciences is a regenerative medical company that specializes in the promotion of its regenerative repair material product line for bone repair.
Shunxi Fund is an investment Fund. It is managed by Beijing State-owned Capital Operations and Management.
Show more...Investment focus
- Industry: Biotechnology, Manufacturing, Artificial Intelligence
- Stage:Series A, Seed, Series B
- Geography: China
Investor stats
- Total investments: 77
- Round size: Seed $2.4M–$20M; Series A $3M–$78M; Series B $14M–$90M
- Lead/follow: 32% lead, 68% follow
Portfolio highlights
- Zhiran Medical — Zhiran Medical is a medical technology company specializing in the precise detection and treatment of neurological disorders using high-throughput, flexible brain-computer interface technology.
- Dingxi Zhichuang — Dingxi Zhichuang is an integrated circuit chip developer specializing in the manufacture, design, and services of integrated circuit chips and products, as well as sales and the manufacturing of semiconductor device special equipment.
- Isin Intelligent — Isin Intelligent is a cloud computing service provider that utilizes FPGAs (a type of semi-custom chip) to realize a new computing paradigm in microwave photonics and optoelectronic parametric oscillators, providing novel solutions to combinatorial optimization problems widely existing in many fields in my country (transportation, finance,pharmaceutical R&D, artificial intelligence, etc.).
Shenzhen Oriental Fortune Capital Co Ltd. is a venture capital firm specializing investment in early venture, mid venture, late venture, emerging growth, Pre-IPO, mature, growth capital stage, mezzanine and new third board investments. The firm typically invests in financial services, telecommunication, new energy, consumer goods, medical treatmentand healthcare, life sciences, internet plus healthy lifestyle industry, logistics, energy technology, information technology, mobile innovation, media, movies and television, culture, pharmaceutical, biological medicine, renewable energy, retail, environmental protection business, consumption, new materials, new agriculture, advanced manufacturing, equipment manufacturing, culture, entertainment, and services. It seeks to invest in China focusing on Shenzhen, Shanghai, Beijing, Xi’an, and Wuhu. The firm also invests in Pearl River Delta region, Yangtze River Delta region, and Circum-Bohai-Sea region. For Pearl River Delta, it covers Guangzhou, Shenzhen, Foshan, Dongguan, Zhongshan, Zhuhai, Huizhou, Jiangmen, and Zhaoqing cities in China. For Yangtze River Delta, the firm covers Shanghai, Nanjing, Wuxi, Changzhou, Suzhou, Nantong, Yancheng, Yangzhou, Zhenjiang, Taizhou, Hangzhou, Ningbo, Jiaxing, Huzhou, Shaoxing, Jinhua, Zhoushan, Taizhou, Hefei, Wuhu, Ma’anshan, Tongling, Anqing, Chuzhou, Chizhou, and Xuancheng cities in China. For the Circum-Bohai-Sea region, it covers Beijing, Tianjin, Shenyang, Dalian, Qingdao, Dandong, Yingkou, Panjin, Fuxin, Huludao, Chaoyang, Shijiazhuang, Baoding, Tangshan, Qinhuangdao, Cangzhou, Langfang, Chengde, Zhangjiakou, Handan, Xingtai, Dongying, Yantai, Weifang, Weihai, Rizhao, and Binzhou cities in China. The firm prefers to invest 20% of its portfolio to early stage, 40% to expansion stage, and 40% to Pre-IPO stage. Shenzhen Oriental Fortune Capital Co Ltd. was formed in November 2007 and is based in Shenzhen, China with offices in Shanghai, China; Beijing, China; and Wuhu, China.
Show more...Investment focus
- Industry: Manufacturing, Software, Artificial Intelligence
- Stage:Series A, Series B, Seed
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 334
- Round size: Seed $1.5M–$100M; Series A $1.5M–$30M; Series B $3.1M–$100M
- Lead/follow: 35% lead, 65% follow
- Last fund: May invest from a new fund soon — last raise in 2015
Portfolio highlights
- Memory tensor — Memory tensor designed with a focus on systematic innovation, grounded firmly in fundamental principles, serves as a powerful tool for scalable and adaptable intelligence. Its architecture emphasizes three core attributes: low cost, ensuring economic feasibility and accessibility; low illusion, reducing overfitting and minimizing hallucinations ormisleading outputs; and high generalization.
- Langsilicon Technology — Langsilicon Technology is an electronic component R&D firm that specializes in the design, development, and sales of silicon-based passive components (capacitors, inductors, and resistors).
- Lightwheel — Light Wheel Intelligence is offers automated, physically precise and controllable, real and generalizable synthetic data solutions to build AI data infrastructure,
WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve theproductivity of advancing healthcare products through cost-effective and efficient solutions,With industry-leading capabilities such as R&D and manufacturing for small molecule drugs, cell and gene therapies, and testing for medical devices, WuXi AppTec's open-access platform is enabling more than 3,900 collaborators from over 30 countries to improve the health of those in need – and to realize our vision that "every drug can be made and every disease can be treated".
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Series A, Series B, Series C
- Geography: United States, China, Israel
Investor stats
- Total investments: 49
- Round size: Series A $6M–$90M; Series B $21M–$130M; Series C $30M–$187M
- Lead/follow: 20% lead, 80% follow
- Last fund: May invest from a new fund soon — raised $250M in 2015
Portfolio highlights
- D3 Bio — D3 Bio is a globally focused biotechnology company focusing on developing and registration of innovative medicines in oncology and immunology. At D3 Bio, our new medicine development approach is fundamentally differentiated. We do not just only start with science in the lab. First, we pinpoint the greatest unmet patient and market needs – whereexisting standard-of-care approaches yield unsatisfactory clinical outcomes. Then we take those insights into the lab to guide the identification of fit for purpose science and technology and define our drug development path.
- ShouTi — ShouTi specializes in the discovery and development of drugs against a type of targets called GPCR. The company develops drugs focused on novel small molecules for multiple unmet medical needs. ShouTi is currently operating in Stealth mode.
- Bioyond Tech — Bioyond Tech utilizes robotics and artificial intelligence technology to provide a new generation of modular products and automation solutions for the life sciences sector.
Entrepreneurship Relay Group manages a fund of more than 4 billion yuan, directly or indirectly.
Show more...Investment focus
- Industry: Manufacturing, Software, Enterprise
- Stage:Series A, Angel, Venture - Series Unknown
- Geography: China
Investor stats
- Total investments: 24
- Round size: Series A $1.5M–$30M
- Lead/follow: 8% lead, 92% follow
Portfolio highlights
- Songying Technology — Songying Technology focuses on the research and development of cloud-native real-time 3D engines and graphics collaboration platforms.
- Spectral Domain Technology — Spectral Domain Technology is a provider of 5G low-orbit broadband terminals, supplying operators, industrial Internet companies, satellite Internet, and government and enterprise customers with ocean communication needs.
- Optical Standard Technology — Optical Standard Technology focuses on the design and manufacture of optical computing chips and optical computing boards for use in scenarios requiring large amounts of AI computing power, such as large model reasoning and training, autonomous driving, smart cities, quantitative finance, AI security.
Tianjin Venture Capital is an investment firm.
Show more...Investment focus
- Industry: Manufacturing, Information Technology, Biotechnology
- Stage:Venture - Series Unknown, Seed
- Geography: China, United States
Investor stats
- Total investments: 110
- Round size: Seed $462k–$15M; Venture - Series Unknown $4.4M–$41M
- Lead/follow: 15% lead, 85% follow
Portfolio highlights
- Yuantian Bio — Yuantian Bio is a biotechnology company specializing in enzymatic regeneration and commercial plastic PET applications. They have achieved low-cost fermentation preparation of over 10 enzyme preparations and large-scale biochemical product preparation.
- Innovec Biotherapeutics — Innovec Biotherapeutics Specialized in gene therapy technology and medication development.
- SiliconFlow — Silicon Mobile Technology is an AI infrastructure company that specilaizes in large models inference and deployment system to reduce the cost in the AIGC and LLM industries.
Legend Capital, a subsidiary of Legend Holdings Ltd., started its vintage year in April, 2001 with a mission to become a top-notch and the most respected venture capital investment manager in China.Managing up to US$700 million across four funds, Legend Capital focuses on driving high-growth ventures with operations substantially based in Chinaor on markets related to China.Legend Capital mainly invests in early stage IT companies, specifically, in sectors of network applications and services, outsourcing and professional services, Infrastructure (IC design/key components), and mid-market growth stage companies in the fields of consumer goods, clean technology, health care, equipment manufacturing and modern services.Among over 60 portfolio companies are Joyo.com (acquired by Amazon.com), SinoCom (0299.HK), Solarfun Power (Nasdaq: SOLF), Spreadtrum Communications (Nasdaq: SPRD), China Sunshine Paper (2002.HK), and VanceInfo (NYSE:VIT), Eyang (0117.HK), etc.As an active investor, Legend Capital provides its portfolio companies extensive business resources and tailored services to assist with business development, company image building, and other critical company building activities on Chinese market so as to add value and maximize returns. Legend Capital is proud and thankful that it has the opportunity to blaze a trail with its innovative practice for China's venture capital industry.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series B, Series A, Series C
- Geography: China, United States, South Korea
Investor stats
- Total investments: 518
- Round size: Series A $2.9M–$93M; Series B $12M–$100M; Series C $15M–$200M
- Lead/follow: 43% lead, 57% follow
- Last fund: Likely still investing — raised $177M in 2021
Portfolio highlights
- Z.ai — The AI Lab behind GLM models, dedicated to inspiring the development of AGI to benefit humanity. https://t.co/gOw7WpwkJt https://t.co/ot9sGVXU8x
- Huixin Bio — Huixin Bio is a developer of exosome purification products and early cancer detection technology.
- Honghu Future Energy — Honghu Fusion is a commercial nuclear fusion startup developing high-temperature superconducting stellarator technology
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Inspiration Capital is an investment firm.
Show more...Investment focus
- Industry: Manufacturing, Artificial Intelligence, Semiconductor
- Stage:Seed, Series A, Angel
- Geography: China
Investor stats
- Total investments: 26
- Round size: Seed $1.5M–$15M; Series A $16M–$16M
- Lead/follow: 31% lead, 69% follow
Portfolio highlights
- Soge Intelligent — Soge Intelligent engages in technology promotion and application services.
- Chipflow Microwave — Chipflow Microwave has developed an intelligent IC design platform that can comprehend design objectives, organize procedures, orchestrate tools, analyze results, and continually iterate and optimize.
- Honghu Future Energy — Honghu Fusion is a commercial nuclear fusion startup developing high-temperature superconducting stellarator technology
Longpan Investment is an investment firm.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Seed, Series B
- Geography: China, United States, Cayman Islands
Investor stats
- Total investments: 44
- Round size: Seed $14M–$60M; Series A $14M–$32M; Series B $14M–$37M
- Lead/follow: 55% lead, 45% follow
Portfolio highlights
- Jingling Zhikang — Jingling Zhikang is technology company specializing in the intersection of medical rehabilitation, robotics, and embodied artificial intelligence. The company focuses on developing intelligent rehabilitation bionic hands and upper-limb prosthetics.
- Hanyue New Materials — Hanyue Advanced Materials is a high-tech company that specializes in single-use biopharmaceutical solutions.
- Lingtai Krypton Biotechnology — Lingtai Krypton Biotechnology is an innovative corporation that specializes in the development of lncRNA drugs.
CITIC Capital Holdings is an alternative investment management and advisory company headquartered in China.
Show more...Investment focus
- Industry: Manufacturing, Health Care, Biotechnology
- Stage:Series A, Series B, Series C
- Geography: China, United States, Japan
Investor stats
- Total investments: 106
- Round size: Series A $3.2M–$230M; Series B $7.2M–$50M; Series C $10M–$220M
- Lead/follow: 40% lead, 60% follow
- Last fund: May invest from a new fund soon — raised $2.8B in 2018
Portfolio highlights
- Yudao Bio — Yudo Bio provides biopharmaceutical products. It has its headquarters in Shanghai in China.
- Genta Kyushu Bio — Genta Kyushu Bio is a cutting edge biotechnology company specializing in the development of precision neuro circuit therapies for central nervous system and ophthalmic diseases. The firm leverages its high throughput screening and drug development platforms to advance innovative treatments utilizing chemogenetics, optogenetics, and gene therapies.
- Xuntu Technology — Xuntu Technology is a leading data intelligence provider specializing in investment research and decision-making solutions.
Jinqiu Fund invests in biotechnology companies
Show more...Investment focus
- Industry: Artificial Intelligence, Robotics, Manufacturing
- Stage:Seed, Series A, Angel
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 35
- Lead/follow: no public data
Portfolio highlights
- MindOn — MindOn is a robotics company that develops artificial intelligence software and algorithms to create humanoid robots.
- Miracle Rabbi — MiracleRabi is an AI-powered trendsetting brand focused on the research, development, and promotion of AI toys, integrating cutting-edge artificial intelligence, interactive technologies, and imaginative design to create engaging, educational, and emotionally intelligent play experiences that inspire creativity and redefine the future of smartentertainment.
- Qingxian Intelligence — Qingxian Intelligence is a smart office and home office technology company. The company focuses on smart, comfortable, and healthy office scenarios.
Tsinghua Capital is an investment firm.
Show more...Investment focus
- Industry: Manufacturing, Artificial Intelligence, Biotechnology
- Stage:Seed, Angel, Series A
- Geography: China, Australia
Investor stats
- Total investments: 74
- Round size: Seed $1.4M–$73M; Angel $425k–$14M; Series A $2.3M–$17M
- Lead/follow: 9% lead, 91% follow
Portfolio highlights
- Xingkeyuan — Star Science is a high-performance lithium battery silicon-carbon negative electrode material research and development company. It has achieved small-scale mass manufacture of nano-silicon as well as the experimental development of high-efficiency silicon-carbon composite materials.
- Qinghao Puzhong — Qinghao Puzhong is a technological development and manufacturing company that produces resin-infiltrated ceramic-based dental restoration materials.
- Zhiyuan Shenlan — Zhiyuan Shenlan focuses on data-driven biomolecule design and manufacturing.
Lucion is an influential professional venture capital institute.
Show more...Investment focus
- Industry: Biotechnology, Manufacturing, Medical
- Stage:Series A, Series B
- Geography: China
Investor stats
- Total investments: 56
- Round size: Series A $1.4M–$539M; Series B $2.8M–$144M
- Lead/follow: 45% lead, 55% follow
Portfolio highlights
- Robot Era — Robot era is an emerging technology business creates embodied intelligence and generic humanoid robot technologies and products. Xingdong Era is committed to the development of universal humanoid robots that can adapt to a wide range of fields, multiple scenarios, and high intelligence, striving to realize the beautiful vision of intelligent robotsentering thousands of households and integrating into the lights of thousands of homes.
- Oricell Therapeutics — OriCell Therapeutics aims to develop drugs with good efficacy and affordable prices for tumor immunotherapy.
- Wutong Sensing Control — Wutong Sensing Control is a leading company that specializes in the research, development, and innovation of cutting-edge robotic mechanics and tactile sensing technologies. With a strong focus on advancing automation systems, the company aims to enhance the precision, efficiency, and adaptability of robotic applications in various industries,including manufacturing, healthcare, and consumer electronics.
Innoangel Fund is an investment firm that invests in early stage companies.
Show more...Investment focus
- Industry: Artificial Intelligence, Robotics, Manufacturing
- Stage:Angel, Seed, Series A
- Geography: China, Canada, Hong Kong
Investor stats
- Total investments: 216
- Round size: Seed $425k–$27M; Angel $425k–$14M; Series A $1.4M–$14M
- Lead/follow: 30% lead, 70% follow
Portfolio highlights
- InfinAstro — InfinAstro is a firm that develops and manufactures rocket engines, rocket launch equipment, rocket control systems, and microsatellites.
- Zhidao Hechuang — Zhidao Hechuang is a comprehensive solution provider for new energy asset management.
- Zhiyuan Shenlan — Zhiyuan Shenlan focuses on data-driven biomolecule design and manufacturing.
Shangshi Fund is an investment firm.
Show more...Investment focus
- Industry: Information Technology, Manufacturing, Artificial Intelligence
- Stage:Series A, Angel, Seed
- Geography: China
Investor stats
- Total investments: 62
- Round size: Seed $1.4M–$73M; Angel $283k–$2.1M; Series A $1.4M–$71M
- Lead/follow: 13% lead, 87% follow
Portfolio highlights
- Approaching.AI — Approaching.AI is an AI Infra company focusing on the important large model application scenarios such as RAG.
- Qianjue Technology — Qianjue Technology is a company that created the first full-stack application-level robot model and offers cloud-based artificial intelligence solutions to robot manufacturers.
- Optical Interconnect Technology —
Gaw Capital Partners is a positioned private equity fund management company that focuses in real estate markets in greater China and other high barrier-to-entry markets globally. Their services includes gateway real estate funds, separate account investments, venture capital, private equity investment and credit investments.
Show more...Investment focus
- Industry: Real Estate, Hotel, Internet
- Stage:Series A, Seed, Series C
- Geography: China, Singapore, United States
Investor stats
- Total investments: 22
- Round size: Seed $3M–$11M; Series A $4.8M–$25M; Series C $11M–$250M
- Lead/follow: 55% lead, 45% follow
- Last fund: May invest from a new fund soon — raised $430M in 2021
Portfolio highlights
- Blackpanda — Asia's premier digital forensics and cyber incident response firm.
- SARELLY SARELLY — SARELLY SARELLY is a gender-neutral and transparent fashion brand, offering affordable luxury to the Hispanic Gen Z community.
- NPX Point Avenue — NPX Point Avenue is an education technology company focused on the fast-growing K-12 private international school market and K-12 after-school training market.
By adopting revolutionary mechanisms, FREES FUND is devoted to change the long-established rules in the venture capital. By leveraging the cutting-edge technologies and resources, FREES FUND aims at investing in great startups and helping them grow into great enterprises that are valuable to our society. We mainly invest in early-stagestartups, and hope to become their first-round institutional investor. Our primary interested areas are broad-sense TMT (Technology, Media, Telecom), B2B and deep technology.
Show more...Investment focus
- Industry: Artificial Intelligence, Health Care, Biotechnology
- Stage:Series A, Seed, Angel
- Geography: China, United States, Singapore
Investor stats
- Total investments: 211
- Round size: Seed $1.4M–$14M; Angel $425k–$17M; Series A $1.4M–$35M
- Lead/follow: 27% lead, 73% follow
- Last fund: May invest from a new fund soon — raised $130M in 2015
Portfolio highlights
- SoundAI — Sound Technology is a science and technology innovation company that specializes in acoustics frontier technology and artificial intelligence interaction. It is committed to lead the more interactive experience of artificial intelligence in the real environment and realize the human-computer interaction vision that "listen to you and know whatyou think".
- Methuselah — Methuselah is a research and development manufacturer of medical nutritional food.
- Chuguang 3D — Chuguang 3D is a optical micro-nano 3D sensor technology platform that focuses on research and development, and manufacturing of micro-nano-level optical three-dimensional sensing and measurement and testing instruments.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!We apply our TransCon technology platform to build a leading, fully integrated biopharma company & make a meaningful difference for patients, caregivers & HCPs.
Show more...Investment focus
- Industry: Life Science, Biotechnology, Pharmaceutical
- Stage:Series A, Series B
- Geography: China
Investor stats
- Total investments: 3
- Round size: Series A $40M–$40M
- Lead/follow: 67% lead, 33% follow
Portfolio highlights
- Visen Pharmaceuticals — Visen Pharmaceuticals is a biotech company focused on developing and commercializing innovative endocrine drugs that address significant unmet needs for patients in Greater China.
Med-Fine Capital is a venture capital firm focusing on early stage investments in China healthcare industry. The company is headquartered in Shanghai with offices in Beijing and Shenzhen.
Show more...Investment focus
- Industry: Medical, Health Care, Biotechnology
- Stage:Series A, Seed, Series B
- Geography: China, Hong Kong, United States
Investor stats
- Total investments: 83
- Round size: Seed $8M–$60M; Series A $3M–$40M; Series B $12M–$60M
- Lead/follow: 31% lead, 69% follow
- Last fund: May invest from a new fund soon — raised $73M in 2019
Portfolio highlights
- Zhuanma Biotech — Zhuanma Biotechnology is a gene editing service provider dedicated to clinically developing effective ultra-small gene editors into genetic therapeutics that are "curable once and for all."
- Tianyikang Biotechnology — Tianyikang Biotechnology focuses on medical research and the development and application of next-generation cell immunotherapy products.
- Beijing Ansong Technology — Beijing Ansong Technology Co., Ltd. is an enterprise focusing on the research and development, production, and sales of orthopedic medical devices. The company cooperates with domestic and foreign universities, research institutes, and doctors in hospitals, and is committed to creating original orthopedic products with independent knowledgeproducts.Beijing Ansong Technology was founded on June 27, 2011 by Liang Tao in Fengtai, Beijing.
Huimei Capital primarily seeks investment in the medical and healthcare ecosystem in a multi-dimensional and three-dimensional manner. It is committed to building a professional investment platform with international vision and local execution, helping early and growing medical and health companies to grow rapidly.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: China, United States, Japan
Investor stats
- Total investments: 35
- Round size: Series A $10M–$251M; Series B $18M–$102M; Series C $23M–$79M
- Lead/follow: 34% lead, 66% follow
Portfolio highlights
- Sniper Medical Technology — Sniper develops accurate and intelligent molecular diagnostic solutions. Taking the next-generation fully automatic digital PCR as a breakthrough, the company has developed a droplet generation method with global independent intellectual property rights - Vibrant Injection technology and created a new path of chip-free droplet generationtechnology. It solves the pain points of high cost and complicated operation of microfluidic technology in practical application and is expected to bring subversive innovation in the field of refined medical testing.
- Osteal Therapeutics — Osteal Therapeutics is a privately-held, clinical-stage pharmaceutical company developing novel musculoskeletal therapeutics to treat orthopedic infections and their consequences.
- Chengdu Pukang Biotechnology Co. — Chengdu Pukang Biotechnology Co., Ltd specializes in the development, production, and supply of high-purity single molecular PEG series derivatives, polypeptide long-acting drug side chains, and their intermediates. The company focuses on serving the pharmaceutical industry with a range of chemical supplies that are crucial for drug development andmanufacturing processes. With a professional R&D team, Chengdu Pukang Biotechnology is dedicated to advancing pharmaceutical intermediates technology and providing solutions that meet the evolving needs of the healthcare sector. The company's commitment to research and development is evident in its continuous efforts to innovate and improve its product offerings to support the pharmaceutical industry.
BMC engaged in asset management, investment management and consulting.
Show more...Investment focus
- Industry: Biotechnology, Medical, Product Research
- Stage:Seed, Series B
- Geography: China
Investor stats
- Total investments: 12
- Round size: Seed $1.4M–$14M
- Lead/follow: 17% lead, 83% follow
Portfolio highlights
- OneTar Biomedicine — OneTar Biomedicine is a biopharma company that develops organoid and oncology drugs.
- Fuan Green Energy Technology — Fuan Green Energy Technology focuses on the research and development of new battery technologies, aiming to improve the energy density and safety of energy storage systems.
- Jingyao Xinhui Semiconductor — Jingyao Xinhui Semiconductor is the indium phosphide optical chip manufacturer company.
Orient Securities Capital Investment is an private equity fund business platform.
Show more...Investment focus
- Industry: Manufacturing, Health Care, Software
- Stage:Series A, Series B, Venture - Series Unknown
- Geography: China, Canada
Investor stats
- Total investments: 45
- Round size: Series A $1.5M–$73M; Series B $1.6M–$100M; Venture - Series Unknown $7.5M–$684M
- Lead/follow: 22% lead, 78% follow
Portfolio highlights
- Ubot Robotics — Ubot Robotics is dedicated to developing leg-and-foot bionic robots and has built a diverse range of bipedal, quadrupedal, hexapodal, and other leg-and-foot bionic robots.
- Kiri Innovation — KIRI Innovation develops affordable and innovative 3D scanners. Phiz 3D Scanner is a low cost, high precision laser 3D scanner that works with smartphones. Using today's phone camera and powerful CPU, a laser 3D scanner has never been so affordable and smart.
- Hefei Maiwei Technology — Maiwei New Materials is a provider of electromagnetic functional materials and structures.
The firm is a 25-year-old global investment firm focused on healthcare with approximately $5.8 billion in AUM, which we have invested in over 290 public and private companies worldwide. Headquartered in Palo Alto, California, with offices in Asia. Our team consists of 50 multi-disciplinary professionals, including, physicians, scientists,entrepreneurs, operating executives, and industry experts. The firm operates as a multi-fund investment platform, covering growth equity, private equity including buyout, venture capital, and public equity. Vivo invests broadly in healthcare across all fund strategies, including biotechnology, pharmaceuticals, medical devices, and healthcare services, with a focus on the largest healthcare markets.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Post-IPO Equity, Series B, Series C
- Geography: United States, China, United Kingdom
Investor stats
- Total investments: 265
- Round size: Series B $28M–$137M; Series C $30M–$142M; Post-IPO Equity $35M–$180M
- Lead/follow: 27% lead, 73% follow
- Last fund: Likely actively investing — fresh fund, raised $740M in 2025
Portfolio highlights
- Serán Bioscience — Leading pharmaceutical innovator offering tailored drug solutions with comprehensive analytical and manufacturing services for biotech and pharma.
- Korsana Biosciences — Korsana Biosciences develops THETA-enabled antibody therapies for neurodegenerative diseases. The company focuses on shuttled monoclonal antibodies that cross the blood-brain barrier to reach central nervous system targets. Its lead program, KRSA-028, is an investigational anti-amyloid beta antibody for Alzheimer’s disease that uses a transferrinreceptor-based shuttle and Fc engineering to improve brain delivery and dosing. Korsana is also advancing additional THETA-based programs for undisclosed neurodegenerative indications.
- Expedition Therapeutics — Redefining Care. Advancing COPD and Other Respiratory Therapies. Expedition Therapeutics is developing novel treatments for inflammatory and respiratory diseases with the potential to fundamentally transform patient care worldwide. ABOUT US At Expedition Therapeutics, we believe that disease-controlling treatments that address fundamental disease mechanisms should be the new standard for chronic obstructive pulmonary disease (COPD). Our
ASBV focuses on early and mid-term venture capital investments.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Seed, Series A, Angel
- Geography: China, Australia, Hong Kong
Investor stats
- Total investments: 28
- Round size: Seed $3M–$14M; Angel $471k–$485k; Series A $1.4M–$34M
- Lead/follow: 46% lead, 54% follow
Portfolio highlights
- Kaiyue Life — Kaiyue Life focuses on small molecule medication research & development for the treatment of human Ras mutant solid tumours.
- Boundary Intelligent Control — Boundary Intelligent is specialized in creating airborne systems, such as flight control systems, that satisfy the needs of civil aircraft, as well as enhancing the ecology of the civil aviation industry and constructing aircraft perception, navigation, decision-making, and planning capabilities.
- Longyue Mechanical and Electrical Technology — Longyue Mechanical and Electrical Technology engaged in technologies, strengthened linkages, and provided commercial aircraft services.
Shenzhen Green Pine Capital Partners Co. Ltd. (“GPCP”) was established in 2007, with the investment team assembled in 2000. GPCP is one of the most time-honored Chinese VC companies that boast experience in areas such as biotech, new materials, new resources and AI, etc. Currently, GPCP manages assets over 15 billion RMB through 21 special fundsand have invested 7 billion RMB into 388 enterprises among which 14 are listed on NEEQ and 48 of them are either listed or acquired by listed companies, including BGI(300676.SZ), Aurora(600666.SH), Nationz Tech(300077.SZ), Foresee(002530.SZ), Qudian(NASDAQ:QD), etc. GPCP invested in the angel round of BGI (Beijing Genomics Institute), Royole, Kuang-Chi, Appotronics, BMF, C-one, Arrayed Materials and other star enterprises.GPCP is based in Shenzhen, with branches in Beijing, Shanghai and Guangzhou. GPCP also runs two GPI incubators and an incubator for overseas Chinese scientists who start businesses in China.
Show more...Investment focus
- Industry: Artificial Intelligence, Biotechnology, Manufacturing
- Stage:Series A, Angel, Series B
- Geography: China, United States, Canada
Investor stats
- Total investments: 244
- Round size: Angel $425k–$3.1M; Series A $1.5M–$60M; Series B $3M–$150M
- Lead/follow: 32% lead, 68% follow
- Last fund: Likely actively investing — fresh fund, raised $42M in 2025
Portfolio highlights
- Enrikenuo — Enrikenuo is a biotechnology company that focuses on the research and development of new generation CAR-NK technology based cell drugs.
- Sungen Biomedical — Sungen Biomedical is an innovative antibody drug R&D enterprise. It has established international standard technology platforms and original biological macromolecular R&D pipelines. Their focus includes therapeutic drugs for cardiovascular and cerebrovascular diseases, tumors, and more.
- Chiplight Technology — Chipligh Technology develops optical interconnect and silicon photonics solutions for AI computing clusters.
BOHE Angel Fund is an investment Fund.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Angel, Seed, Series A
- Geography: China
Investor stats
- Total investments: 16
- Round size: Seed $14M–$15M; Angel $1.4M–$100M
- Lead/follow: 19% lead, 81% follow
Portfolio highlights
- KangaBio — KangaBio is a biotech business specializing in developing novel medicines to meet unmet medical needs. It helps in developing prodrugs of immune-stimulating medicines and other multi-specific biologics to minimize toxicities and boost treatment efficacy for already established targets.
- PrinoPharma — PrinoPharma focuses on developing novel druggable sites targeting difficult-to-drug or existing druggable targets.
- Qinhao Pharmaceutical — Qinhao Pharmaceutical is harmaceutical enterprises with a gathering of humanities and innovation.
Highlight Capital is an investment firm dedicated to support healthcare companies to generate robust and sustained growth prospect.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: China, United States, South Korea
Investor stats
- Total investments: 179
- Round size: Seed $10M–$84M; Series A $3.1M–$73M; Series B $7.6M–$70M
- Lead/follow: 35% lead, 65% follow
- Last fund: Likely still investing — raised $563M in 2021
Portfolio highlights
- Genuine Rhythm — Genuine Rhythm is an innovative AI Agent technology developer specializing in bespoke agent creation, advanced algorithm R&D, and rigorous security compliance solutions tailored to diverse enterprise needs.
- Ziwei Technology — Ziwei Technology is a high-tech company making returnable spacecraft.
- Differential Robotics — Differential Robotics is a robotics company providing research, design, and development of aerial robots and intelligent autonomous drones.
Life Science Investor funding in China at a glance
Stats across 381 deals from 691 investors.
Access all 691 investors in China Life Science startups.
Open ListFAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Life Science Investors in China investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 691 investors investing in China Life Science startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!